Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Consilient Health Limited, 5<sup>th</sup> Floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland
Cilostazol 100 mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Odourless or almost odourless, white or almost white, round, flat, bevelled edge tablets with no physical faults, no spots and no extraneous matters on the surface of tablet. The tablets are with stylized E engraving and 602 code on one side and no sign on the other side. The diameter of tablets is about 8 mm. The height of tablets is about 3.05 mm. |
One tablet contains 100 mg of cilostazol.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels. Studies in animals and in man (in vivo and ex vivo) have shown that cilostazol causes reversible inhibition of platelet aggregation. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline |
28 (2x14) or 56 (4x14) tablets in PVC/PVdC//Aluminium blisters in carton box with package leaflet. Not all pack sizes may be marketed.
Consilient Health Limited, 5th Floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland
PL 24837/0048
24/04/2014
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.